Figure 3

ATG5^Mye−/− mice display alteration in the hepatic immune cell activation. (A) MFI of MHC II in CD11b⁺ F4/80⁺ cells in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. (B) Number of CD4⁺ PD1⁺ T cells per liver in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. (C) Number of CD8⁺ PD1⁺ T cells and CD8⁺ Granzyme B⁺ cells per liver in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. (D) MFI of TRAIL in NK1.1⁺ cells in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. (E) CD8⁺ cells/Treg cells ratio in WT or ATG5^Mye−/− mice 10 months after DEN or saline solution administration. Data are shown as mean ± SEM. *, p < 0.05 for WT Control vs WT DEN, # for ATG5^Mye−/− Control vs ATG5^Mye−/− DEN and &, p < 0.05 for WT vs ATG5^Mye−/−. n = 3–6 for WT mice Control; n = 4 for ATG5^Mye−/− mice Control; n = 6–10 for WT mice DEN; n = 6–13 for ATG5^Mye−/− mice DEN.